Key Points
- CEO Insider Buy: Greenwich LifeSciences CEO Snehal Patel purchased 2,900 shares on Dec. 30 at an average price of $21.73 for $63,017, increasing his holdings to 5,595,102 shares valued at roughly $121.6 million (a 0.05% increase).
- This trade continues a sustained insider buying pattern—Patel made several recent purchases (e.g., 4,100 shares on Dec. 18 at $12.62; 4,600 on Nov. 25 at $8.37; 10,600 on Nov. 7 at $8.43), which investors often view as management confidence.
- Analyst and financial context: HC Wainwright raised its price target to $50 with a Buy rating, but the company remains unprofitable (negative P/E and expected EPS around -0.8 for the year) and the stock trades in a 52-week range of $7.78–$30.82.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 2,900 shares of the firm's stock in a transaction that occurred on Tuesday, December 30th. The shares were purchased at an average cost of $21.73 per share, for a total transaction of $63,017.00. Following the completion of the acquisition, the chief executive officer owned 5,595,102 shares in the company, valued at $121,581,566.46. This represents a 0.05% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Snehal Patel also recently made the following trade(s):
- On Thursday, December 18th, Snehal Patel bought 4,100 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $12.62 per share, with a total value of $51,742.00.
- On Tuesday, November 25th, Snehal Patel purchased 4,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $8.37 per share, with a total value of $38,502.00.
- On Friday, November 7th, Snehal Patel acquired 10,600 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $8.43 per share, with a total value of $89,358.00.
- On Friday, October 31st, Snehal Patel acquired 2,300 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $9.26 per share, with a total value of $21,298.00.
Greenwich LifeSciences Stock Performance
Shares of GLSI opened at $19.47 on Friday. The firm's 50-day simple moving average is $11.10 and its two-hundred day simple moving average is $10.92. The stock has a market cap of $269.66 million, a PE ratio of -13.34 and a beta of 1.47. Greenwich LifeSciences, Inc. has a fifty-two week low of $7.78 and a fifty-two week high of $30.82.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.30). Equities research analysts predict that Greenwich LifeSciences, Inc. will post -0.8 EPS for the current year.
Key Headlines Impacting Greenwich LifeSciences
Here are the key news stories impacting Greenwich LifeSciences this week:
- Positive Sentiment: HC Wainwright raised its price target to $50 (from $39) and continues to carry a "Buy" rating, a bullish analyst signal that can support longer-term upside. Greenwich LifeSciences price target raised to $50 from $39 at HC Wainwright
- Positive Sentiment: Company publicity: Greenwich announced a claimed new milestone in breast cancer prevention — a potentially material clinical/strategic development that could drive future revenue or partnership interest if substantiated. New milestone in breast cancer prevention claimed by Greenwich
- Positive Sentiment: Insider buy: CEO Snehal Patel purchased 2,900 shares at about $21.73 (SEC filing), a small additional personal stake that investors often view as a vote of confidence by management. SEC insider transaction filing
- Negative Sentiment: Continued expected losses: HC Wainwright's detailed estimates project quarterly EPS of about ($0.30–$0.31) across 2025–2026 and FY2026 EPS of ($1.24), highlighting that the company remains unprofitable — a substantive headwind that can limit valuation and keep stock volatility high.
Analyst Ratings Changes
Several brokerages recently weighed in on GLSI. HC Wainwright boosted their price target on shares of Greenwich LifeSciences from $39.00 to $50.00 and gave the stock a "buy" rating in a research report on Tuesday. Wall Street Zen raised shares of Greenwich LifeSciences from a "sell" rating to a "hold" rating in a research report on Saturday, December 27th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Greenwich LifeSciences in a report on Monday. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $47.50.
View Our Latest Analysis on Greenwich LifeSciences
Hedge Funds Weigh In On Greenwich LifeSciences
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Greenwich LifeSciences during the 2nd quarter worth approximately $25,000. Bank of America Corp DE boosted its position in shares of Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock worth $82,000 after acquiring an additional 1,322 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after purchasing an additional 3,168 shares during the last quarter. HighTower Advisors LLC purchased a new position in shares of Greenwich LifeSciences in the 1st quarter valued at approximately $147,000. Finally, Strs Ohio purchased a new stake in shares of Greenwich LifeSciences in the first quarter valued at approximately $177,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.
Greenwich LifeSciences Company Profile
(
Get Free Report)
Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company's product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.
Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
